Approved indications (United States): Leukine is approved (given intravenously or subcutaneously) to: shorten time to neutrophil recovery and reduce severe or fatal infections after induction chemotherapy for acute myeloid leukemia (AML) in adults 55 years and older; mobilize hematopoietic progenitor cells into blood for collection and autologous transplantation in adult cancer patients; accelerate myeloid reconstitution after autologous peripheral blood progenitor cell or bone-marrow transplantation in adults and children ≥2 years with NHL, ALL, or Hodgkin lymphoma; accelerate myeloid reconstitution after allogeneic bone-marrow transplantation from HLA-matched related donors in adults and children ≥2 years; treat delayed neutrophil recovery or graft failure after autologous or allogeneic bone-marrow transplantation in adults and children ≥2 years; and increase survival in adults and pediatric patients from birth to 17 years who are acutely exposed to myelosuppressive doses of radiation (H-ARS).

Common off-label uses and evidence level: Clinicians sometimes use Leukine off-label for prevention or treatment of chemotherapy-induced febrile neutropenia in non-myeloid cancers, myelodysplastic syndromes, aplastic anemia, severe chronic neutropenia, agranulocytosis from non‑chemotherapy drugs, and HIV-related neutropenia, generally supported by small trials, case series, or compendia rather than large registration studies. It has also been explored experimentally in conditions such as Alzheimer’s disease and COVID-19–related lung injury, but these investigational uses are not FDA-approved and evidence is still limited.

Efficacy expectations in approved uses: In AML and transplant settings, neutrophil counts usually begin to rise within several days, and Leukine typically shortens the duration of severe neutropenia and time to ANC recovery by a few days compared with no growth factor, which can reduce serious infections, antibiotic use, and hospital stay; overall survival benefit is clearest in the radiation (H-ARS) setting, where animal data show improved survival when started as soon as possible after exposure.

Comparison with other growth factors: Compared with G-CSF drugs (such as filgrastim or pegfilgrastim), Leukine (a GM-CSF) stimulates a broader range of myeloid and dendritic cells and may offer advantages where broader immune activation or platelet effects are desired, but G-CSFs are used more commonly for routine chemotherapy-related neutropenia and generally have more extensive randomized human data.

General administration: Leukine is given by intravenous (IV) infusion or subcutaneous (SC) injection, usually once daily; it is not related to meals and is most often administered in a clinic or hospital, although some patients may be trained to give SC injections at home using premeasured vials and syringes.

Typical adult and pediatric dosing ranges (selected indications):

• AML induction (adults ≥55 years): 250 mcg/m²/day IV over about 4 hours, starting around day 11 or 4 days after finishing induction chemotherapy when the marrow is hypoplastic, continued until ANC >1500/mm³ for 3 consecutive days or up to 42 days.
• Autologous PBPC mobilization and collection (adults): 250 mcg/m²/day as a 24‑hour IV infusion or once‑daily SC injection, continued through the leukapheresis period.
• Autologous PBPC or bone-marrow transplant (adults and children ≥2 years): 250 mcg/m²/day IV over 2–24 hours or SC once daily beginning shortly after infusion of cells or marrow and continued until ANC >1500/mm³ for 3 consecutive days.
• Allogeneic bone-marrow transplant (adults and children ≥2 years): 250 mcg/m²/day IV over about 2 hours starting 2–4 hours after marrow infusion (and at least 24 hours after chemotherapy or radiotherapy) and continued until ANC >1500/mm³ for 3 consecutive days.
• Delayed engraftment or graft failure after transplant (adults and children ≥2 years): typically 250 mcg/m²/day IV over 2 hours for 14 days, with possible repeat courses if neutrophil recovery does not occur.
• Acute radiation exposure (H-ARS; adults and pediatric patients from birth to 17 years): once-daily SC injection of 7 mcg/kg for patients >40 kg, 10 mcg/kg for 15–40 kg, or 12 mcg/kg for <15 kg, started as soon as possible after suspected or confirmed myelosuppressive radiation and continued until ANC remains >1000/mm³ for 3 CBCs or exceeds 10,000/mm³ after the radiation nadir.

Key administration and monitoring instructions: Leukine should not be given at the same time as, or within 24 hours before or after, cytotoxic chemotherapy or radiotherapy. Complete blood counts with differential are checked regularly (often at least twice weekly, or about every 3 days in H-ARS) to guide duration and any dose adjustments; doses are reduced or temporarily held if ANC or WBC counts become very high or if significant adverse reactions occur.

Missed doses: If a scheduled hospital or clinic dose is missed, the care team typically reschedules it as soon as feasible; patients who self-inject should contact their oncology or transplant team for instructions and should not double up doses without medical guidance.

Overdose: Very high doses can cause marked leukocytosis and more intense side effects such as fever, shortness of breath, rash, and rapid heart rate; management is usually to stop Leukine, monitor blood counts and symptoms, and provide supportive care until counts and clinical status normalize.

Common side effects (often mild to moderate):

• Fever, chills, fatigue or malaise, headache, and a general flu-like feeling.
• Nausea, vomiting, diarrhea, abdominal pain, mouth sores, and loss of appetite or weight.
• Skin reactions or rash, itching, hair loss, and injection-site or infusion-site reactions.
• Fluid retention and edema (swelling), which may show as ankle or leg swelling or rapid weight gain.
• Liver and metabolic laboratory changes, high blood sugar, or mild changes in kidney tests.

These effects most often start in the first days of treatment, are dose-related, and usually improve when the dose is reduced or treatment is stopped.

Serious or rare adverse effects needing urgent attention:

• Severe allergic or anaphylactic reactions (widespread rash or hives, swelling of face or throat, trouble breathing, wheezing, fast heartbeat, dizziness or fainting).
• Infusion-related reactions (sudden shortness of breath, chest tightness, flushing, low blood pressure, or fainting during or soon after an infusion).
• Marked fluid overload or capillary leak syndrome (rapid weight gain, swelling of legs or abdomen, difficulty breathing, fluid around the lungs or heart).
• Worsening lung problems (new or worsening shortness of breath, cough, or low oxygen), or pleural/pericardial effusions.
• Heart rhythm problems or other cardiac events (palpitations, irregular or very fast heart rate, chest pain).
• Very high white-blood-cell counts or platelet counts, which can increase the risk of complications and require dose adjustment or interruption.

Warnings and precautions:

• Do not use in patients with a history of serious hypersensitivity to GM-CSF, sargramostim, yeast-derived products, or any component of the formulation.
• Use with particular caution in people with preexisting lung disease, congestive heart failure, significant edema, pleural or pericardial effusions, or a history of significant cardiac arrhythmias, as Leukine can worsen fluid retention and cardiopulmonary symptoms.
• Monitor closely in patients with liver or kidney impairment because fluid shifts and laboratory abnormalities may be harder to manage.
• In myeloid malignancies, Leukine can theoretically stimulate malignant cells; therapy should be stopped if disease progression or blast regrowth is seen.
• Pregnancy: human data are limited and animal studies suggest potential harm to the fetus, so use only if potential benefit justifies the risk; breastfeeding is generally not recommended during treatment and for at least 2 weeks after the last dose.
• Neonates and very low–birth-weight infants should not receive benzyl‑alcohol–containing formulations, so only preservative‑free reconstitution solutions should be used in this age group.

Overall safety compared with similar drugs: Leukine has a well-characterized safety profile similar to other colony-stimulating factors, but may cause somewhat more flu-like symptoms, gastrointestinal upset, and fluid retention than some G-CSFs; all such agents require blood-count monitoring and careful use in patients with cardiopulmonary disease.

Side-effect reporting and safety updates: Patients and caregivers in the United States can report suspected side effects to the FDA’s MedWatch program (online or by calling 1-800-FDA-1088) and may check the FDA website or the manufacturer’s site for the latest safety communications on Leukine.

Drug and supplement interactions:

• Cytotoxic chemotherapy and radiotherapy: Leukine must not be administered simultaneously with, or within 24 hours before or after, most cytotoxic chemotherapy or radiotherapy because actively dividing marrow cells may be more sensitive to damage and severe myelosuppression can result.
• Other myeloproliferative or growth-factor drugs: Concomitant use with agents that also stimulate bone-marrow proliferation (including other colony-stimulating factors) can increase the risk of excessively high white-blood-cell counts and related complications and is generally avoided unless specifically directed by a specialist.
• Lithium and systemic corticosteroids: These medicines can enhance white-blood-cell production and may potentiate Leukine’s myeloproliferative effects or adverse events, so closer monitoring of blood counts is recommended if they must be used together.
• Other prescription, OTC, and herbal products: No major CYP-mediated interactions are known, but patients should review all medicines and supplements with their care team so that overlapping toxicities (for example fluid retention, cardiotoxicity, or lung toxicity) can be considered.
• Food, alcohol, and diagnostics: No specific food interactions are known, and moderate alcohol has no direct pharmacologic interaction, though heavy alcohol use can impair immune function; Leukine does not usually interfere with standard imaging or laboratory tests aside from changing blood counts.

Precautions and populations requiring special care:

• Use cautiously in patients with congestive heart failure, preexisting edema, pleural or pericardial effusions, significant lung disease, or prior serious arrhythmias, because Leukine can worsen fluid retention and cardiopulmonary status.
• Patients with liver or kidney disease may be more prone to fluid shifts and laboratory abnormalities and should be monitored more closely.
• In neonates and very small infants, avoid benzyl‑alcohol–containing diluents and use preservative‑free formulations only.
• Pregnant patients should receive Leukine only when clearly indicated, after risk–benefit discussion; breastfeeding is generally avoided during treatment and for at least 2 weeks afterward.
• Patients with myeloid malignancies or prior myelodysplastic or myeloproliferative disorders require careful hematologic oversight, and Leukine should be stopped if there is evidence of disease progression.

Monitoring needs: Regular CBCs with differential are mandatory during therapy, often at least twice weekly (or every ~3 days in H-ARS) to guide dosing and duration; clinicians may also monitor electrolytes, liver and kidney function, weight, fluid status, vital signs, and cardiopulmonary symptoms, especially in high‑risk patients or those receiving prolonged courses.

Q: Is Leukine a type of chemotherapy?
A: No, Leukine is not chemotherapy; it is a biologic growth factor (GM-CSF) that helps your bone marrow make more white blood cells so you can recover from chemotherapy, transplant, or radiation faster and lower your risk of severe infection.

Q: How long does it take Leukine to start raising my white blood cell count?
A: In many patients, neutrophil counts begin to rise within several days of starting Leukine, and recovery to safer levels often occurs a few days sooner than it would without a growth factor, though the exact timing varies with the treatment setting and your underlying condition.

Q: Can I give myself Leukine injections at home?
A: In some cases, especially during stem-cell mobilization or after transplant, your team may train you or a caregiver to give subcutaneous Leukine injections at home, but this is done only after you receive detailed instruction on dose calculation, injection technique, and safe storage and disposal.

Q: How is Leukine different from drugs like Neupogen or Neulasta?
A: Neupogen and Neulasta are G-CSF medicines that mainly stimulate neutrophils, while Leukine is a GM-CSF that also activates monocytes, macrophages, and dendritic cells; G-CSFs are more commonly used for routine chemotherapy-related neutropenia, whereas Leukine is often used in transplant settings, specific AML regimens, and as a medical countermeasure after radiation exposure.

Q: What should I do if I miss a scheduled dose of Leukine?
A: Contact your oncology or transplant team as soon as you realize a dose was missed so they can decide whether to give it late, adjust the schedule, or skip it; do not double the next dose or change the schedule on your own.

Q: Can I use Leukine if I am pregnant or breastfeeding?
A: Because human data are limited and animal studies suggest possible risk to the fetus, Leukine is used in pregnancy only when clearly needed, and breastfeeding is generally not recommended during treatment and for at least 2 weeks after the last dose, so these situations should always be discussed with your specialist in advance.

Storage: If Leukine vials are supplied for home use, keep them in the original carton in a refrigerator at 36°F to 46°F (2°C to 8°C), do not freeze or shake, protect from light, and do not use the medicine past the expiration date on the vial.

In-use stability: For multi-dose vials, your provider may instruct you to refrigerate an opened vial and use it only for a limited time (commonly up to 20 days from first use); mark the first-use date on the carton and discard any remaining medicine after the instructed time.

Disposal: Use a new sterile needle and syringe for each injection, do not reuse needles or syringes, and place used needles, syringes, and empty or partially used vials in an FDA-cleared sharps container or a heavy puncture-resistant container with a secure lid; follow local or pharmacy instructions for disposal of sharps and unused medication.